Library · Free to embed
Research & reference library
Original charts, tools, and explainers we've built to make sense of retatrutide and the broader GLP-1 drug class. Each piece is sourced, dated, and free to embed on any site with attribution.
8 pieces · 4 free to embed
Cross-trial weight loss: every published GLP-1 obesity drug
Normalized side-by-side chart of mean weight loss across every published Phase 2/3 obesity-drug trial — semaglutide, tirzepatide, retatrutide, orforglipron, and more.
OpenReference assetEmbeddableThe GLP-1 receptor map: which drugs hit which receptors
A canonical visual reference for the GLP-1 drug class — which agonists target GLP-1, GIP, glucagon, amylin, and emerging targets, in one matrix.
OpenToolGLP-1 cost calculator: monthly cost by drug, channel, and insurance
An interactive calculator that estimates monthly out-of-pocket cost for retatrutide, tirzepatide, and semaglutide across cash-pay, telehealth, and insured channels.
OpenReference assetEmbeddableGLP-1 timeline: every milestone from exenatide (2005) to today
A two-decade timeline of the GLP-1 drug class — every approval, pivotal trial, and major regulatory action that shaped today's obesity-drug landscape.
OpenExplainerHow to read the TRIUMPH-1 readout: a pre-positioned guide
What numbers to look for, what comparisons matter, and what the headline weight-loss figure will and won't tell you when Lilly's pivotal Phase 3 trial reads out.
OpenReference assetEmbeddableRetatrutide molecular structure, annotated
Retatrutide as a 39-residue peptide with a fatty-acid side chain, broken down position by position with the receptor-binding regions highlighted.
OpenExplainerWhat 'investigational' actually means: a guide to the FDA process
An evergreen explainer for any reader trying to make sense of a drug that's in trials but not approved — Phase 1 to label, IND to NDA, breakthrough designation, and what it all means for access.
OpenExplainerWhy glucagon — the 'raise blood sugar' hormone — is in a weight-loss drug
Glucagon is supposed to raise blood sugar. So why does activating its receptor with retatrutide make people lose weight without spiking glucose? The most counterintuitive thing about the drug, explained.
OpenWant to embed a chart? Each reference asset includes a one-click embed code. Free for any site, including commercial ones, with a visible link back to the source page.